CClinicalTrials.gg
Sign In
RecruitingNCT02333110Updated May 12, 2026

GRID Therapy as Palliative Radiation for Patients With Advanced and Symptomatic Tumors

An interventional study of spatially fractionated radiation therapy in Patients With Symptomatic or Bulky Tumors (More Than 8 cm) or With Tumors Resistant to Radiation, sponsored by Sir Mortimer B. Davis - Jewish General Hospital. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-12.

Sponsored by Sir Mortimer B. Davis - Jewish General Hospital · Not applicable, Interventional, and Supportive care

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Palliative radiation therapy represents 40% of the on-going radiation at the Jewish General Hospital. In a traditional palliative radiation treatment to bulky or radioresistant tumors, radiotherapy schema varies from 24 to 30 Gys given in 3 to 10 fractions, depending on the tumor size, tumor location and tumor pathology. However, for many patients this treatment involves considerable toxicity, travel and time spent at the hospital. Spatially fractionated radiation (SFR) is an alternative technique that consists in delivering one single treatment, given through a grid containing holes. The present study is proposing to validate SFR as a safe and effective mean to palliate patients with symptomatic bulky tumors (more than 8 cm) or with tumors known to be resistant to radiation.

02

Conditions studied

  • Patients With Symptomatic or Bulky Tumors (More Than 8 cm) or With Tumors Resistant to Radiation
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patient with histologically or cytologically confirmed malignancy. All malignant histologies/cytologies are eligible.
  • Patient with bulky tumor (larger than 8cm), or with a tumor known to be resistant to radiation (eg. Melanoma, hypernephroma, sarcoma), or with a tumor previously irradiated with a palliative intent requiring more than 1 fraction of radiation
  • Patient planned to undergo palliative radiation therapy treatments to one of the following 5 sites: extremities, neck, chest, abdomen and pelvis
  • WHO performance status of 0-2
  • Aged 18 years or older
  • Ability to sign and understand an informed consent form

Exclusion criteria

Exclusion Criteria:

  • Potentially curable patient
  • Previous palliative radiation with hypofractionation
  • Tumor located near the spinal cord or in the brain
  • Pregnant or nursing woman
04

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    GRID radiation therapy

    A single dose of 15-20Gys of spatially fractionated radiation therapy

    Radiation: spatially fractionated radiation therapy

Interventions

  • Radiationspatially fractionated radiation therapy

    A single dose of 15-20Gys of spatially fractionated radiation therapy

    Also known as: GRID radiation therapy

05

What researchers measure

Primary outcomes

  1. Symptom relief, as measured using the CTCAE grading system (v4.0) and pain questionnaire

    Time frame: 3 months post treatment

Secondary outcomes

  1. Acute toxicity of treatment, as measured using the CTCAE grading system (v4.0)

    Time frame: 1 week

  2. Long-term toxicity of treatment, as measured using the CTCAE grading system (v4.0)

    Time frame: 3, 6, 9, 12 months

  3. Cost-effectiveness, as measured by evaluating the cost of the procedure per patient and the efficacy of treatment with regards to symptom relief and tumor response

    Time frame: 3 months

  4. Tumor response, measured on CT-scan

    Time frame: 8 weeks

06

Study locations

1 of 1 sites recruiting
  • Sir Mortimer Jewish General Hospital
    Montreal, Quebec H3T 1E2, Canada
    Recruiting
07

Registry details

Key details

Study ID
NCT02333110
Lead sponsor
Sir Mortimer B. Davis - Jewish General Hospital
Responsible party
Dr. Te Vuong (Director, Radiation-oncology department, Sir Mortimer B. Davis - Jewish General Hospital) — Principal investigator
First posted
Jan 7, 2015
Start date
Jan 2015
Primary completion
Dec 2026 (estimated)
Completion
Dec 2027 (estimated)
Last update
May 12, 2026

Study contacts

Luciana Poggi, PhD
Contact
luciana.poggi.trinidad.ccomtl@ssss.gouv.qc.ca
514-340-8222 ext. 28443
Te Vuong, MD
principal investigator · Sir Mortimer Jewish General Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

Sir Mortimer B. Davis - Jewish General Hospital

Start the discussion